$146.00
+ Free ShippingIndications
1. Differentiated Thyroid Cancer (DTC): For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
2. Renal Cell Carcinoma (RCC):
– In combination with pembrolizumab, for adult patients with advanced renal cell carcinoma (RCC).
3. Hepatocellular Carcinoma (HCC): For patients with unresectable hepatocellular carcinoma (HCC).
4. Endometrial Carcinoma (EC): In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC).
Availability: 100 in stock
Lenvatinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that suppresses vascular endothelial growth factor receptors (VEGFR 1-3), fibroblast growth factor receptors (FGFR 1-4), platelet-derived growth factor receptor α (PDGFRα), KIT, and RET.
Lenvatinib can be used to treat various cancers, including thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.
Reviews
There are no reviews yet.